Navigation Links
Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
Date:3/28/2011

mpletion of the Offer; and(C)

without limiting any of the foregoing, no Regulatory Authority becomes entitled to suspend, terminate or withhold any grant, development assistance or other financial assistance to which any member of the ChemGenex Group is or may be otherwise entitled or to require or accelerate repayment of any grant, development assistance or other financial assistance previously provided to any member of the ChemGenex Group.(d)

HSRNo objection being received and the period of 30 days expiring (or earlier terminated) from the date of the filing by Cephalon CXS of a merger / acquisition notification as required under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.(e)

No prescribed occurrences(i)

Between the time beginning when the Bidder's Statement is given to ChemGenex and ending at the end of the Offer Period, none of the following occurrences happens:(A)

ChemGenex converts all or any of the ChemGenex Shares into a larger or smaller number of ChemGenex Shares;(B)

any member of the ChemGenex Group resolves to reduce its share capital in any way;(C)

any member of the ChemGenex Group enters into a buy-back agreement or resolves to approve the terms of a buy-back agreement under section 257C(1) or 257D(1) of the Corporations Act; (D)

any member of the ChemGenex Group issues shares (other than pursuant to Disclosed Options or the convertible notes on issue to Cephalon International) or grants an option over its shares, or agrees to make such an issue or grant such an option; (E)

any member of the ChemGenex Group issues, or agrees to issue, convertible notes;(F)

any member of the ChemGenex Group disposes, or agrees to dispose, of the whole, or a substantial part, of its business or property;(G)

any member of the ChemGenex Group charges, or agrees to charge, the whole, or a substantial part, of its business or property;(H)

any member of the C
'/>"/>

SOURCE Cephalon, Inc.; ChemGenex Pharmaceuticals Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Cephalon Wins FENTORA Patent Suit Against Watson
2. Cephalon Announces Definitive Agreement to Acquire Gemin X
3. Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
4. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
5. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
6. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
7. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
8. Cephalon to Webcast Investor Day
9. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
10. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
11. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... , April 28, 2015  Illnesses know no work schedule ... places of business. If you,ve ever woken up the morning ... sick as the proverbial dog, or if you,ve been putting ... how to fit it into your schedule, you,ve experienced this ... House Call Doctor Los Angeles offers an alternative for busy ...
(Date:4/28/2015)... 28, 2015 UPM Pharmaceuticals, an independent drug ... prestigious "2015 Industry Choice Award" in the Mid-sized and ... Life Science Leader magazine during the annual CMO ... York City on March 18, 2015. The ... service organizations based on survey responses from thousands of ...
(Date:4/28/2015)... 28, 2015  The Physician-Patient Alliance for Health ... , RRT has joined the Physician-Patient Alliance Board ... well-respected Registered Respiratory Therapist who has practiced in the ... for his excellent work on critical patient safety issues. ... Care (AARC) at various conferences addressing the need ...
Breaking Medicine Technology:Your Health and Your Schedule Should not be at War 2UPM Pharmaceuticals Awarded The 2015 Industry Choice Award for Mid-sized and Emerging Pharma 2Noted Respiratory Therapist and AARC Representative Gene Gantt Joins Physician-Patient Alliance for Health & Safety Advisory Board 2
(Date:4/28/2015)... Pittsburgh, PA (PRWEB) April 28, 2015 ... by Blair A. Jobe, MD, FACS , has ... replacing esophageal tissue with extracellular matrix (ECM) can help ... lethal form of esophageal cancer. , ECM is a ... for cell attachment and migration and signals that guide ...
(Date:4/28/2015)... 2015 As the Muscular Dystrophy ... services programs, the organization has hired Scientific Program ... MDA from Fidelity Biosciences Research Initiative where, as ... in neurodegenerative diseases such as Alzheimer’s Disease, and ... time at Fidelity, she was a junior faculty ...
(Date:4/28/2015)... 2015 Researchers from four US medical ... a steroid prior to pemetrexed (Alimta) chemotherapy may keep ... Click here to read the full story on ... Raabe College of Pharmacy in Ohio, Stanford Cancer Institute ... Healthcare in Kentucky gave a single dose of dexamethasone ...
(Date:4/28/2015)... 2015 SeniorCare.com has published the ... reality problem Americans have regarding aging and long-term care ... care services as they age, 63% of Americans do ... In the report, Carol Marak of SeniorCare.com interviewed 44 ... Health Care Association and The Scan Foundation. The experts ...
(Date:4/28/2015)... Enrollment in programs designed to coordinate ... in April, according to the editors of Atlantic ... Eligibles Database , an online subscription resource that ... community. This is a 14% increase since the ... January, but only covers about a quarter of ...
Breaking Medicine News(10 mins):Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 3Health News:MDA Adds Neurological Disease Expert to Research Team 2Health News:MDA Adds Neurological Disease Expert to Research Team 3Health News:Study Finds New Regimen May Ward Off Skin Rash from Common Mesothelioma Drug, According to Surviving Mesothelioma 2Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2Health News:Enrollment in Duals Programs Increases 14%, New AIS Database Finds 2
... complicated. Thomas Jefferson University biochemistry researchers have shown ... insect molting hormone doesn,t activate and repress genes as once ... out-competed by a heme-binding receptor to repress the same genes ... For the last 20 years, the nuclear receptor known ...
... U.S. Food and Drug Administration and the National Institutes ... of tobacco users to monitor and assess the behavioral ... The initiative, called the Tobacco Control Act National Longitudinal ... collaboration on tobacco regulatory research since Congress granted FDA ...
... and diagnosis of open angle glaucoma important so that treatment ... developing to prevent or avoid further vision loss. Writing in ... Engineering and Informatics , researchers in the US have analyzed ... so that patients can be screened at an earlier stage ...
... , THURSDAY, Oct. 6 (HealthDay News) -- ,Anemia ... have different types of surgery, not just heart operations, a ... anemia have worse outcomes after heart surgery, but anemia,s impact ... deficient in red blood cells. For the new ...
... had been given DES, the first synthetic form of estrogen, ... in the womb (in utero) is associated with many reproductive ... conditions. The results of this analysis, conducted by researchers at ... of Health, and collaborators across the country, were published Oct. ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. ... forms of multiple sclerosis appears to reduce relapse rates and ... 3 trial. The experimental drug, teriflunomide, is one of ... and may, if approved, be a good choice for many ...
Cached Medicine News:Health News:Nuclear receptors battle it out during metamorphosis in new fruit fly model 2Health News:FDA and NIH announce joint study on tobacco use and risk perceptions 2Health News:Detecting glaucoma before it blinds 2Health News:Anemia Could Add to Surgical Risks 2Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 2Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 3Health News:Experimental MS Drug Shows Promise 2Health News:Experimental MS Drug Shows Promise 3
... Introducing the new large ... new handpieces function as both ... the ultimate in flexibility. Its ... always wanted with the security ...
... 7600 Oscillating Saw offers unparalleled ... thanks to its 14.4V NiMH ... head may be rotated into ... any plane and will accept ...
... Breakthrough in Battery Powered Orthopedic Systems., ... new addition to the Hall® Surgical line ... System is the first and only software ... market. It is a full-function orthopedic power ...
... Introducing the new large ... Our new handpieces function ... electric instruments, offering the ... the versatility the industry ...
Medicine Products: